HALO:NGS-Halozyme Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 56.07

Change

0.00 (0.00)%

Market Cap

USD 1.64B

Volume

2.22M

Analyst Target

USD 33.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Halozyme Therapeutics Inc is a biopharmaceutical company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.38 (+0.76%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+0.53 (+0.11%)

USD 65.38B
ARGX argenx NV ADR

+11.35 (+1.98%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+1.53 (+0.50%)

USD 32.75B
ONC BeiGene, Ltd.

+0.35 (+0.14%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.38 (+1.16%)

USD 18.35B
SMMT Summit Therapeutics PLC

-0.49 (-2.69%)

USD 13.53B
INSM Insmed Inc

+1.95 (+2.80%)

USD 11.84B
INCY Incyte Corporation

+0.25 (+0.38%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-1.02 (-1.76%)

USD 11.29B

ETFs Containing HALO

ROYL:AU BetaShares Global Royalti.. 3.88 % 0.00 %

-0.16 (-1.02%)

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.12 % 0.00 %

+0.04 (+-1.02%)

N/A
JSML Janus Henderson Small Cap.. 2.26 % 0.50 %

+0.40 (+-1.02%)

USD 0.18B
JSMD Janus Henderson Small/Mid.. 2.13 % 0.50 %

+0.30 (+-1.02%)

USD 0.49B
FSGS First Trust SMID Growth S.. 1.12 % 0.00 %

-0.04 (-1.02%)

USD 0.03B
RSSL:AU Global X Russell 2000 Etf 0.81 % 0.00 %

-0.09 (-1.02%)

N/A
VTWG Vanguard Russell 2000 Gro.. 0.63 % 0.20 %

+1.37 (+-1.02%)

USD 0.95B
AGED:SW iShares Ageing Population.. 0.57 % 0.00 %

+0.02 (+-1.02%)

N/A
R2US:SW SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

-0.52 (-1.02%)

USD 4.18B
XRS2:SW 0.33 % 0.00 %

N/A

N/A
VTWO Vanguard Russell 2000 Ind.. 0.32 % 0.15 %

+0.16 (+-1.02%)

USD 11.92B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.60 (+-1.02%)

N/A
GSC Goldman Sachs ETF Trust 0.00 % 1.25 %

+0.05 (+-1.02%)

N/A
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

+0.01 (+-1.02%)

USD 0.02B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+1.00 (+-1.02%)

N/A
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

+0.29 (+-1.02%)

USD 0.69B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

+2.04 (+-1.02%)

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

+0.63 (+-1.02%)

USD 10.02B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

+0.09 (+-1.02%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

-1.50 (-1.02%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+3.20 (+-1.02%)

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+0.29 (+-1.02%)

USD 0.30B
UWM ProShares Ultra Russell20.. 0.00 % 0.95 %

+0.21 (+-1.02%)

USD 0.30B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.43 (-1.02%)

USD 4.13B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.26 (-1.02%)

USD 4.13B
RTWO:LSE L&G Russell 2000 US Small.. 0.00 % 0.00 %

-0.56 (-1.02%)

USD 0.19B
RTWP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

-67.50 (-1.02%)

USD 0.19B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-210.50 (-1.02%)

USD 1.80B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-1.17 (-1.02%)

USD 1.80B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.59 (-1.02%)

USD 4.13B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.09 (+-1.02%)

N/A
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

-0.90 (-1.02%)

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.12 (-1.02%)

USD 2.91B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

-0.49 (-1.02%)

USD 0.09B
AFSM First Trust Active Factor.. 0.00 % 0.00 %

-0.04 (-1.02%)

USD 0.03B
IBBJ 0.00 % 0.00 %

N/A

N/A
RSSL Global X Funds 0.00 % 0.00 %

-0.05 (-1.02%)

USD 1.34B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.28% 81% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.28% 81% B- 85% B
Trailing 12 Months  
Capital Gain 26.60% 83% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.60% 83% B 80% B-
Trailing 5 Years  
Capital Gain 131.79% 92% A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 131.79% 92% A 84% B
Average Annual (5 Year Horizon)  
Capital Gain 15.77% 67% D+ 75% C
Dividend Return 15.77% 67% D+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.82% 82% B 56% F
Risk Adjusted Return 49.55% 95% A 79% B-
Market Capitalization 1.64B 97% N/A 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.52 32% 50%
Price/Book Ratio 16.83 10% 8%
Price / Cash Flow Ratio 16.94 3% 17%
Price/Free Cash Flow Ratio 12.60 7% 30%
Management Effectiveness  
Return on Equity 147.06% 100% 100%
Return on Invested Capital 25.40% 89% 90%
Return on Assets 18.50% 99% 99%
Debt to Equity Ratio 413.88% 5% 5%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.